These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 10714552)
1. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors. Recchia F; Accorsi P; Bonfini T; De Filippis S; Grimaldi M; Corrao G; Rosselli M; Amiconi G; Iacone A; Rea S J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470 [TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163 [TBL] [Abstract][Full Text] [Related]
5. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study. Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial. Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699 [TBL] [Abstract][Full Text] [Related]
11. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891 [TBL] [Abstract][Full Text] [Related]
12. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498 [TBL] [Abstract][Full Text] [Related]
13. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma. Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500 [TBL] [Abstract][Full Text] [Related]
14. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889 [TBL] [Abstract][Full Text] [Related]
15. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192 [TBL] [Abstract][Full Text] [Related]
16. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350 [TBL] [Abstract][Full Text] [Related]
17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
18. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Rosenfeld CS; Bolwell B; LeFever A; Taylor R; List A; Fay J; Collins R; Andrews F; Pallansch P; Schuster MW; Resta D; Levitt D; Nemunaitis J Bone Marrow Transplant; 1996 Feb; 17(2):179-83. PubMed ID: 8640163 [TBL] [Abstract][Full Text] [Related]
19. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]